An open-label study of algorithm-based treatment versus treatment-as-usual for patients with schizophrenia

Jinichi Hirano, Koichiro Watanabe, Takefumi Suzuki, Hiroyuki Uchida, Ryosuke Den, Taishiro Kishimoto, Takashi Nagasawa, Yusuke Tomita, Koichiro Hara, Hiromi Ochi, Yoshimi Kobayashi, Mutsuko Ishii, Akane Fujita, Yoshihiko Kanai, Megumi Goto, Hiromi Hayashi, Kanako Inamura, Fumiko Ooshima, Mariko Sumida, Tomoko Ozawa & 10 others Kayoko Sekigawa, Maki Nagaoka, Kae Yoshimura, Mika Konishi, Ataru Inagaki, Takuya Saito, Nobutaka Motohashi, Masaru Mimura, Yoshiro Okubo, Motoichiro Kato

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objective: The use of an algorithm may facilitate measurement-based treatment and result in more rational therapy. We conducted a 1-year, open-label study to compare various outcomes of algorithm-based treatment (ALGO) for schizophrenia versus treatment-as-usual (TAU), for which evidence has been very scarce. Methods: In ALGO, patients with schizophrenia (Diagnostic and Statistical Manual of Mental Disorders, fourth edition) were treated with an algorithm consisting of a series of antipsychotic monotherapies that was guided by the total scores in the positive and negative syndrome scale (PANSS). When posttreatment PANSS total scores were above 70% of those at baseline in the first and second stages, or above 80% in the 3rd stage, patients proceeded to the next treatment stage with different antipsychotics. In contrast, TAU represented the best clinical judgment by treating psychiatrists. Results: Forty-two patients (21 females, 39.0 10.9 years-old) participated in this study. The baseline PANSS total score indicated the presence of severe psychopathology and was significantly higher in the ALGO group (n=25; 106.9 ± 20.0) than in the TAU group (n = 17; 92.2 ± 18.3) (P = 0.021). As a result of treatment, there were no significant differences in the PANSS reduction rates, premature attrition rates, as well as in a variety of other clinical measures between the groups. Despite an effort to make each group unique in pharmacologic treatment, it was found that pharmacotherapy in the TAU group eventually became similar in quality to that of the ALGO group. Conclusion: While the results need to be carefully interpreted in light of a hard-to-distinguish treatment manner between the two groups and more studies are necessary, algorithm-based antipsychotic treatments for schizophrenia compared well to treatment-as-usual in this study.

Original languageEnglish
Pages (from-to)1553-1564
Number of pages12
JournalNeuropsychiatric Disease and Treatment
Volume9
DOIs
Publication statusPublished - 2013 Oct 10

Fingerprint

Schizophrenia
Therapeutics
Antipsychotic Agents
Psychopathology
Diagnostic and Statistical Manual of Mental Disorders
Psychiatry

Keywords

  • Algorithm
  • Measurement-based treatment
  • Open-label clinical trial
  • Schizophrenia
  • Treatment-as-usual

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

An open-label study of algorithm-based treatment versus treatment-as-usual for patients with schizophrenia. / Hirano, Jinichi; Watanabe, Koichiro; Suzuki, Takefumi; Uchida, Hiroyuki; Den, Ryosuke; Kishimoto, Taishiro; Nagasawa, Takashi; Tomita, Yusuke; Hara, Koichiro; Ochi, Hiromi; Kobayashi, Yoshimi; Ishii, Mutsuko; Fujita, Akane; Kanai, Yoshihiko; Goto, Megumi; Hayashi, Hiromi; Inamura, Kanako; Ooshima, Fumiko; Sumida, Mariko; Ozawa, Tomoko; Sekigawa, Kayoko; Nagaoka, Maki; Yoshimura, Kae; Konishi, Mika; Inagaki, Ataru; Saito, Takuya; Motohashi, Nobutaka; Mimura, Masaru; Okubo, Yoshiro; Kato, Motoichiro.

In: Neuropsychiatric Disease and Treatment, Vol. 9, 10.10.2013, p. 1553-1564.

Research output: Contribution to journalArticle

Hirano, J, Watanabe, K, Suzuki, T, Uchida, H, Den, R, Kishimoto, T, Nagasawa, T, Tomita, Y, Hara, K, Ochi, H, Kobayashi, Y, Ishii, M, Fujita, A, Kanai, Y, Goto, M, Hayashi, H, Inamura, K, Ooshima, F, Sumida, M, Ozawa, T, Sekigawa, K, Nagaoka, M, Yoshimura, K, Konishi, M, Inagaki, A, Saito, T, Motohashi, N, Mimura, M, Okubo, Y & Kato, M 2013, 'An open-label study of algorithm-based treatment versus treatment-as-usual for patients with schizophrenia', Neuropsychiatric Disease and Treatment, vol. 9, pp. 1553-1564. https://doi.org/10.2147/NDT.S46108
Hirano, Jinichi ; Watanabe, Koichiro ; Suzuki, Takefumi ; Uchida, Hiroyuki ; Den, Ryosuke ; Kishimoto, Taishiro ; Nagasawa, Takashi ; Tomita, Yusuke ; Hara, Koichiro ; Ochi, Hiromi ; Kobayashi, Yoshimi ; Ishii, Mutsuko ; Fujita, Akane ; Kanai, Yoshihiko ; Goto, Megumi ; Hayashi, Hiromi ; Inamura, Kanako ; Ooshima, Fumiko ; Sumida, Mariko ; Ozawa, Tomoko ; Sekigawa, Kayoko ; Nagaoka, Maki ; Yoshimura, Kae ; Konishi, Mika ; Inagaki, Ataru ; Saito, Takuya ; Motohashi, Nobutaka ; Mimura, Masaru ; Okubo, Yoshiro ; Kato, Motoichiro. / An open-label study of algorithm-based treatment versus treatment-as-usual for patients with schizophrenia. In: Neuropsychiatric Disease and Treatment. 2013 ; Vol. 9. pp. 1553-1564.
@article{38ab40f509a843b482c3c833b031166a,
title = "An open-label study of algorithm-based treatment versus treatment-as-usual for patients with schizophrenia",
abstract = "Objective: The use of an algorithm may facilitate measurement-based treatment and result in more rational therapy. We conducted a 1-year, open-label study to compare various outcomes of algorithm-based treatment (ALGO) for schizophrenia versus treatment-as-usual (TAU), for which evidence has been very scarce. Methods: In ALGO, patients with schizophrenia (Diagnostic and Statistical Manual of Mental Disorders, fourth edition) were treated with an algorithm consisting of a series of antipsychotic monotherapies that was guided by the total scores in the positive and negative syndrome scale (PANSS). When posttreatment PANSS total scores were above 70{\%} of those at baseline in the first and second stages, or above 80{\%} in the 3rd stage, patients proceeded to the next treatment stage with different antipsychotics. In contrast, TAU represented the best clinical judgment by treating psychiatrists. Results: Forty-two patients (21 females, 39.0 10.9 years-old) participated in this study. The baseline PANSS total score indicated the presence of severe psychopathology and was significantly higher in the ALGO group (n=25; 106.9 ± 20.0) than in the TAU group (n = 17; 92.2 ± 18.3) (P = 0.021). As a result of treatment, there were no significant differences in the PANSS reduction rates, premature attrition rates, as well as in a variety of other clinical measures between the groups. Despite an effort to make each group unique in pharmacologic treatment, it was found that pharmacotherapy in the TAU group eventually became similar in quality to that of the ALGO group. Conclusion: While the results need to be carefully interpreted in light of a hard-to-distinguish treatment manner between the two groups and more studies are necessary, algorithm-based antipsychotic treatments for schizophrenia compared well to treatment-as-usual in this study.",
keywords = "Algorithm, Measurement-based treatment, Open-label clinical trial, Schizophrenia, Treatment-as-usual",
author = "Jinichi Hirano and Koichiro Watanabe and Takefumi Suzuki and Hiroyuki Uchida and Ryosuke Den and Taishiro Kishimoto and Takashi Nagasawa and Yusuke Tomita and Koichiro Hara and Hiromi Ochi and Yoshimi Kobayashi and Mutsuko Ishii and Akane Fujita and Yoshihiko Kanai and Megumi Goto and Hiromi Hayashi and Kanako Inamura and Fumiko Ooshima and Mariko Sumida and Tomoko Ozawa and Kayoko Sekigawa and Maki Nagaoka and Kae Yoshimura and Mika Konishi and Ataru Inagaki and Takuya Saito and Nobutaka Motohashi and Masaru Mimura and Yoshiro Okubo and Motoichiro Kato",
year = "2013",
month = "10",
day = "10",
doi = "10.2147/NDT.S46108",
language = "English",
volume = "9",
pages = "1553--1564",
journal = "Neuropsychiatric Disease and Treatment",
issn = "1176-6328",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - An open-label study of algorithm-based treatment versus treatment-as-usual for patients with schizophrenia

AU - Hirano, Jinichi

AU - Watanabe, Koichiro

AU - Suzuki, Takefumi

AU - Uchida, Hiroyuki

AU - Den, Ryosuke

AU - Kishimoto, Taishiro

AU - Nagasawa, Takashi

AU - Tomita, Yusuke

AU - Hara, Koichiro

AU - Ochi, Hiromi

AU - Kobayashi, Yoshimi

AU - Ishii, Mutsuko

AU - Fujita, Akane

AU - Kanai, Yoshihiko

AU - Goto, Megumi

AU - Hayashi, Hiromi

AU - Inamura, Kanako

AU - Ooshima, Fumiko

AU - Sumida, Mariko

AU - Ozawa, Tomoko

AU - Sekigawa, Kayoko

AU - Nagaoka, Maki

AU - Yoshimura, Kae

AU - Konishi, Mika

AU - Inagaki, Ataru

AU - Saito, Takuya

AU - Motohashi, Nobutaka

AU - Mimura, Masaru

AU - Okubo, Yoshiro

AU - Kato, Motoichiro

PY - 2013/10/10

Y1 - 2013/10/10

N2 - Objective: The use of an algorithm may facilitate measurement-based treatment and result in more rational therapy. We conducted a 1-year, open-label study to compare various outcomes of algorithm-based treatment (ALGO) for schizophrenia versus treatment-as-usual (TAU), for which evidence has been very scarce. Methods: In ALGO, patients with schizophrenia (Diagnostic and Statistical Manual of Mental Disorders, fourth edition) were treated with an algorithm consisting of a series of antipsychotic monotherapies that was guided by the total scores in the positive and negative syndrome scale (PANSS). When posttreatment PANSS total scores were above 70% of those at baseline in the first and second stages, or above 80% in the 3rd stage, patients proceeded to the next treatment stage with different antipsychotics. In contrast, TAU represented the best clinical judgment by treating psychiatrists. Results: Forty-two patients (21 females, 39.0 10.9 years-old) participated in this study. The baseline PANSS total score indicated the presence of severe psychopathology and was significantly higher in the ALGO group (n=25; 106.9 ± 20.0) than in the TAU group (n = 17; 92.2 ± 18.3) (P = 0.021). As a result of treatment, there were no significant differences in the PANSS reduction rates, premature attrition rates, as well as in a variety of other clinical measures between the groups. Despite an effort to make each group unique in pharmacologic treatment, it was found that pharmacotherapy in the TAU group eventually became similar in quality to that of the ALGO group. Conclusion: While the results need to be carefully interpreted in light of a hard-to-distinguish treatment manner between the two groups and more studies are necessary, algorithm-based antipsychotic treatments for schizophrenia compared well to treatment-as-usual in this study.

AB - Objective: The use of an algorithm may facilitate measurement-based treatment and result in more rational therapy. We conducted a 1-year, open-label study to compare various outcomes of algorithm-based treatment (ALGO) for schizophrenia versus treatment-as-usual (TAU), for which evidence has been very scarce. Methods: In ALGO, patients with schizophrenia (Diagnostic and Statistical Manual of Mental Disorders, fourth edition) were treated with an algorithm consisting of a series of antipsychotic monotherapies that was guided by the total scores in the positive and negative syndrome scale (PANSS). When posttreatment PANSS total scores were above 70% of those at baseline in the first and second stages, or above 80% in the 3rd stage, patients proceeded to the next treatment stage with different antipsychotics. In contrast, TAU represented the best clinical judgment by treating psychiatrists. Results: Forty-two patients (21 females, 39.0 10.9 years-old) participated in this study. The baseline PANSS total score indicated the presence of severe psychopathology and was significantly higher in the ALGO group (n=25; 106.9 ± 20.0) than in the TAU group (n = 17; 92.2 ± 18.3) (P = 0.021). As a result of treatment, there were no significant differences in the PANSS reduction rates, premature attrition rates, as well as in a variety of other clinical measures between the groups. Despite an effort to make each group unique in pharmacologic treatment, it was found that pharmacotherapy in the TAU group eventually became similar in quality to that of the ALGO group. Conclusion: While the results need to be carefully interpreted in light of a hard-to-distinguish treatment manner between the two groups and more studies are necessary, algorithm-based antipsychotic treatments for schizophrenia compared well to treatment-as-usual in this study.

KW - Algorithm

KW - Measurement-based treatment

KW - Open-label clinical trial

KW - Schizophrenia

KW - Treatment-as-usual

UR - http://www.scopus.com/inward/record.url?scp=84885942474&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885942474&partnerID=8YFLogxK

U2 - 10.2147/NDT.S46108

DO - 10.2147/NDT.S46108

M3 - Article

VL - 9

SP - 1553

EP - 1564

JO - Neuropsychiatric Disease and Treatment

JF - Neuropsychiatric Disease and Treatment

SN - 1176-6328

ER -